Liquid Biopsy Market: as Guardant360 CDx accumulates companion diagnostic indications across an ever-widening set of tumour types and targeted therapies, a single FDA-approved liquid biopsy platform is converting from a single-purpose diagnostic test into the default companion testing infrastructure that pharmaceutical partners build new targeted therapy launches around, so each additional indication compounds the platform’s clinical utility and payer coverage leverage without requiring a new core assay validation, and this same indication-stacking dynamic is now extending from tissue-based companion diagnostics into blood-based primary cancer screening following Guardant’s Shield colorectal cancer screening approval.

The global liquid biopsy market size was USD 11.48 Billion in 2025 and is expected to register a revenue CAGR of 13.8% during the forecast period. Market revenue growth is driven by factors such as Guardant Health’s Shield blood test establishing the first FDA-approved primary blood-based screening option for colorectal cancer, Guardant360 CDx’s continued accumulation of companion diagnostic indications across an expanding range of targeted therapies, and Natera’s Signatera minimal residual disease monitoring platform driving sustained, rapid company-level revenue growth. The first driving factor is Guardant Health’s Shield blood test, which received FDA approval on July 29, 2024 as the first blood test approved as a primary screening option for colorectal cancer, covering more than 45 million Medicare beneficiaries. The approval was supported by the ECLIPSE study, published in The New England Journal of Medicine in March 2024, which demonstrated 83% sensitivity for colorectal cancer and 90% specificity for advanced neoplasia, establishing the clinical evidence base for blood-based primary cancer screening at population scale. The second driving factor is Guardant360 CDx’s continued accumulation of companion diagnostic indications, extending an already-approved liquid biopsy platform into new tumour types and targeted therapy combinations without requiring a new core assay validation for each addition. Guardant360 CDx received its 25th companion diagnostic indication in January 2026, when the FDA approved it as a companion diagnostic to identify BRAF V600E-mutant metastatic colorectal cancer patients who may benefit from BRAFTOVI in combination with cetuximab and chemotherapy, extending coverage to more than 300 million covered lives across Medicare and commercial payers. The third driving factor is Natera’s Signatera minimal residual disease monitoring platform, which has driven the company’s overall revenue to USD 1.697 billion in FY2024, growing 56.7% year over year, reflecting rapid adoption of liquid biopsy technology for post-treatment cancer recurrence monitoring. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way each additional Guardant360 CDx companion diagnostic indication widens the platform’s payer coverage and pharmaceutical partnership base without requiring the underlying liquid biopsy assay itself to be re-validated, letting one already-approved core platform capture incremental companion diagnostic revenue across a continuously expanding set of targeted therapies. Once a liquid biopsy platform earns its first companion diagnostic approval, each additional indication added for a new targeted therapy or tumour type adds new billable testing volume and reinforces payer coverage without requiring the underlying assay to be independently re-validated from scratch, so the value of an approved liquid biopsy companion diagnostic platform compounds as the number of therapies referencing it grows. As a result, demand and revenue share are concentrating around liquid biopsy platforms with the broadest base of approved companion diagnostic indications and the deepest pharmaceutical partnership relationships, and the forecast tilts toward comprehensive, multi-indication platforms rather than single-biomarker or single-therapy-area tests. For instance, Guardant360 CDx reached 25 approved and active companion diagnostic indications by January 2026, spanning non-small cell lung cancer, breast cancer, and colorectal cancer, with an additional approval for Boehringer Ingelheim’s HERNEXEOS in HER2-mutant non-small cell lung cancer following shortly after, illustrating how the same underlying assay continues to accumulate indication-driven revenue without a new platform validation for each addition. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is Guardant Health’s Shield blood test, which established the first FDA-approved liquid biopsy option for primary colorectal cancer screening at population scale. Primary cancer screening requires a fundamentally different regulatory and clinical evidence bar than companion diagnostic testing, since a screening test is applied to an asymptomatic population rather than a population already diagnosed with cancer, and Shield’s FDA approval as a primary screening option demonstrates that liquid biopsy technology has cleared this higher bar for at least one cancer type, so the approval represents a genuine category expansion rather than an incremental improvement. Shield received FDA approval on July 29, 2024 as the first blood test approved as a primary screening option for colorectal cancer, covering more than 45 million Medicare beneficiaries, supported by the ECLIPSE study published in The New England Journal of Medicine in March 2024, which demonstrated 83% sensitivity for colorectal cancer and 90% specificity for advanced neoplasia. The recent record shows the pace. Guardant Health launched a nationwide, multi-year collaboration with Quest Diagnostics to expand access to Shield and accelerate screening adoption, and expanded Shield to include multi-cancer detection capability with a large-scale real-world data initiative. The effect on the market is that liquid biopsy technology is genuinely extending beyond its historical companion diagnostic and monitoring applications into population-scale primary cancer screening, a substantially larger addressable testing volume category. These are some of the key factors driving revenue growth of the market.

The second driver is the continued expansion of Guardant360 CDx’s companion diagnostic indication count, extending an already-validated liquid biopsy platform into new tumour types and targeted therapy combinations. Pharmaceutical companies developing a new targeted therapy need a companion diagnostic to identify eligible patients, and partnering with an already-approved platform with an established regulatory and payer coverage track record is faster and lower-risk than developing a new companion diagnostic from scratch, so Guardant360 CDx’s accumulating indication count and its attractiveness as a pharmaceutical partner are directly linked. Guardant360 CDx received its 25th companion diagnostic indication in January 2026, identifying BRAF V600E-mutant metastatic colorectal cancer patients eligible for BRAFTOVI combination therapy, and received a subsequent approval as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS in HER2-mutant non-small cell lung cancer, extending coverage to more than 300 million covered lives across Medicare and commercial payers. The effect on the market is that Guardant360 CDx has become a default companion diagnostic infrastructure choice for pharmaceutical companies launching new targeted oncology therapies, converting the platform into a recurring revenue engine that grows with each new drug approval referencing it. These are some of the key factors driving revenue growth of the market.

“Guardant360 CDx reached its 25th FDA-approved companion diagnostic indication in January 2026, with coverage extending to more than 300 million covered lives across Medicare and commercial payers, illustrating how a single already-approved liquid biopsy platform compounds revenue as pharmaceutical partners continue building new targeted therapy launches around it.”

The third driver is the rapid scaling of minimal residual disease monitoring as a distinct liquid biopsy application, led by Natera’s Signatera platform. MRD monitoring addresses a clinical need, detecting cancer recurrence after treatment before it becomes symptomatic or visible on imaging, that neither companion diagnostic testing nor primary screening directly serves, and this distinct clinical use case is what has allowed Signatera to scale as an independent liquid biopsy revenue driver alongside, rather than in competition with, companion diagnostic testing. Natera reported FY2024 revenue of USD 1.697 billion, growing 56.7% year over year, driven substantially by Signatera MRD liquid biopsy adoption across multiple cancer types for post-treatment recurrence monitoring. The effect on the market is that MRD monitoring has established itself as a third major liquid biopsy application category, alongside companion diagnostics and primary screening, with its own distinct growth trajectory and competitive dynamics. These are some of the key factors driving revenue growth of the market.

However, the liquid biopsy market faces adoption constraints from the sensitivity limitations of blood-based testing relative to tissue biopsy for certain cancer types and stages, reimbursement and coverage variability across different liquid biopsy application categories, and the cost and specialised infrastructure requirements that comprehensive liquid biopsy testing depends on. Because circulating tumor DNA concentration varies significantly by cancer type, tumour stage, and individual tumour biology, blood-based liquid biopsy sensitivity, while improving substantially as demonstrated by the ECLIPSE study’s 83% colorectal cancer sensitivity, has not yet universally matched tissue biopsy sensitivity across all cancer types and disease stages, meaning tissue biopsy remains clinically necessary in a meaningful share of cases even as liquid biopsy adoption expands into new applications, and physicians must exercise clinical judgement regarding when liquid biopsy alone is sufficient versus when tissue confirmation remains warranted. Reimbursement and coverage variability is a second constraint, since companion diagnostic testing, minimal residual disease monitoring, and primary cancer screening applications each face distinct payer coverage determination processes with different evidentiary requirements, and coverage for newer application categories such as multi-cancer early detection screening remains meaningfully less established than for companion diagnostic testing, which has built up more than two decades of coverage precedent since the first companion diagnostic approvals. Cost and testing infrastructure requirements are the third constraint, since comprehensive liquid biopsy testing requires specialised laboratory infrastructure, sequencing capacity, and bioinformatics capability that not every healthcare system, particularly in lower-resource domestic settings and internationally, has established, meaning realised testing volume growth in these settings will lag the underlying clinical demand and regulatory approval pace documented in leading markets. These factors substantially limit liquid biopsy market growth over the forecast period.

Based on product, the global liquid biopsy market is segmented into circulating tumor DNA (ctDNA) assays, circulating tumor cells (CTC) assays, and exosome and other biomarker assays. Circulating tumor DNA assays hold the largest revenue share, because ctDNA-based testing underpins both Guardant360 CDx’s companion diagnostic platform and Natera’s Signatera MRD monitoring platform, which suits the technology’s dominant position across the market’s two largest application categories. Circulating tumor cells and exosome-based assays remain established in specific research and specialty clinical applications, but neither has matched ctDNA’s commercial scale across companion diagnostic and MRD monitoring applications.

Based on biomarker, the global liquid biopsy market is segmented into circulating tumor DNA, circulating tumor cells, and cell-free RNA and methylation markers. Circulating tumor DNA holds the largest revenue share, reflecting its established clinical validation across companion diagnostic, MRD monitoring, and primary screening applications, which suits the biomarker’s use in both Guardant360 CDx and Shield. Cell-free RNA and methylation markers are expected to register rapid revenue growth in the global liquid biopsy market over the forecast period, driven by expanding multi-cancer early detection research applications, which is why these biomarker categories represent an active area of ongoing clinical validation investment.

Companion diagnostics/therapy selection application is expected to account for the largest revenue share in the global liquid biopsy market during the forecast period

Based on application, the global liquid biopsy market is segmented into companion diagnostics/therapy selection, minimal residual disease monitoring, and cancer screening/early detection. Companion diagnostics/therapy selection holds the largest revenue share, reflecting Guardant360 CDx’s 25 accumulated FDA-approved indications and broad payer coverage, which suits the application category’s established, multi-decade regulatory and reimbursement precedent. Cancer screening/early detection is expected to register the fastest revenue growth rate in the global liquid biopsy market over the forecast period, driven directly by Shield’s FDA approval as a primary colorectal cancer screening option and its Medicare coverage of more than 45 million beneficiaries, which is why this application represents the newest and highest-volume-potential category in the market.

Based on regional analysis, the liquid biopsy market in North America accounted for largest revenue share in 2025. The United States leads because it is the jurisdiction where Guardant Health’s Shield and Guardant360 CDx and Natera’s Signatera hold their core FDA approvals and Medicare coverage, and because these companies concentrate significant commercial and clinical development activity in the country. Guardant Health’s nationwide collaboration with Quest Diagnostics to expand Shield access launched first within the United States market, leveraging the country’s extensive reference laboratory infrastructure. The concentration of FDA approval activity, Medicare coverage decisions, and leading liquid biopsy company commercial operations in the United States also means new liquid biopsy applications are typically launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national liquid biopsy markets within Europe. The region’s CE-marking regulatory pathway under the In Vitro Diagnostic Regulation moves somewhat more deliberately than the FDA’s single-agency approval pathway, and national health system coverage decisions for newer applications such as primary screening remain less established than in the United States. The result is steady rather than rapid growth, shaped more by regulatory and coverage cadence than by underlying clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and South Korea represent the three largest national liquid biopsy markets within the region. Rising cancer incidence and expanding precision oncology infrastructure investment in China are driving new liquid biopsy demand from a comparatively lower testing penetration base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate-to-rapid revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national liquid biopsy markets within the region. Oncology centres in both countries are gradually adopting liquid biopsy testing for companion diagnostic applications, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised sequencing reagents and equipment that Latin American laboratories depend on through 2026, slowing adoption beyond the region’s main cancer centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial liquid biopsy markets within the GCC. The UAE is the most established liquid biopsy market on the continent given its concentrated private oncology infrastructure, while the wider Gulf states and broader African markets are still building the precision oncology and molecular testing infrastructure that liquid biopsy adoption depends on.